RENALYTIX AI

Result of General Meeting

May 15, 2020

Download full announcement

Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that at the general meeting of the Company held today the resolution to cancel the share premium account of the Company and to grant the Company the general authority to make market purchases of its own shares were passed. 99.99% (12,665,883 votes) of the votes were cast in favour of the resolution.

The Company is currently making the necessary court applications to enable it to proceed with the share buyback and will issue further updates at the appropriate time.

Enquiries

Renalytix AI plc	www.renalytixai.com
James McCullough, CEO	Via Walbrook PR
Stifel (Nominated Adviser & Joint Broker)	Tel: 020 7710 7600
Alex Price / Jonathan Senior / Ben Maddison (Investment Banking)	
N+1 Singer (Nominated Adviser & Broker)	Tel: 020 7496 3000
Aubrey Powell / James White / George Tzimas (Corporate Finance)	
Tom Salvesen / Mia Gardner (Corporate Broking)	
Walbrook PR Limited	Tel: 020 7933 8780
	renalytix@walbrookpr.com
Paul McManus	Mob: 07980 541 893
Lianne Cawthorne	07584 391 303

About Kidney Disease

Kidney disease is now recognised as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control estimates there that 15% of United States adults or 37 million people currently have kidney disease. It is reported that 9 out of 10 adults with chronic kidney disease do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD[*]. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day 13 patients die in the United States while waiting for a kidney transplant.

*https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical *in vitro* diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com